Adam Hutchings | Managing Director

Adam Hutchings, Managing Director, Dolon

Adam is Managing Director of Dolon - an innovative, strategic market access consultancy specialising in rare diseases. A health economist by training, he has over 15 years’ market access experience in consulting and the pharmaceutical industry, including roles at Aventis, GlaxoSmithKline and Baxter Healthcare. He is an expert in healthcare policy relating to pricing, reimbursement, and patient access to orphan drugs and treatments for rare diseases. 


Day 1 Orphan 14th Nov @ 16:35

At what price? Addressing the most difficult question in rare diseases

  • The complexity of pricing in rare diseases
  • Factors that affect pricing decisions
  • Implications for pricing practices
  • How to ensure a sustainable orphan drug business model for all stakeholders

back to speakers